DOCSLIB.ORG

Artin TARGETING ESTROGEN RECEPTOR AS a STRATEGY for PERSONALIZED MEDICINE in OVARIAN CANCER by Courtney Lynn Andersen A.A., Libe

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Artin TARGETING ESTROGEN RECEPTOR AS a STRATEGY for PERSONALIZED MEDICINE in OVARIAN CANCER by Courtney Lynn Andersen A.A., Libe TARGETING ESTROGEN RECEPTOR AS A STRATEGY FOR PERSONALIZED MEDICINE IN OVARIAN CANCER by Courtney Lynn Andersen A.A., Liberal Arts & Sciences, Middlesex Community College, 2008 B.S., Biological Sciences, University of Massachusetts Lowell, 2011 Submitted to the Graduate Faculty of the School of Medicine in partial fulfillment of the requirements for the degree of PhD in Molecular Pharmacology University of Pittsburgh artin 2016 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE This dissertation was presented by Courtney L. Andersen It was defended on February 16, 2016 and approved by Don DeFranco, PhD, Professor, Pharmacology & Chemical Biology Adrian Lee, PhD, Professor, Pharmacology & Chemical Biology, Anda Vlad, MD, PhD, Professor, Obstetrics, Gynecology, & Reproductive Sciences Robert Edwards, MD, Chair, Obstetrics and Gynecology, Magee-Womens Hospital of UPMC Dissertation Advisor: Steffi Oesterreich, PhD, Professor, Pharmacology & Chemical Biology ii Copyright © by Courtney L. Andersen 2016 iii TARGETING ESTROGEN RECEPTOR AS A STRATEGY FOR PERSONALIZED MEDICINE IN OVARIAN CANCER Courtney L. Andersen, PhD University of Pittsburgh, 2016 Ovarian cancer comprises a diverse set of diseases that are difficult to detect and treat successfully. Improving outcomes for ovarian cancer patients is contingent upon identifying targeted, individualized therapeutic strategies. One promising but under-utilized target is estrogen receptor-alpha (ER). ER is expressed in ~70% of epithelial ovarian cancers and epidemiologic studies implicate a role for estrogen in ovarian tumorigenesis. Further, clinical data suggest that a subset of ovarian cancer patients benefit from endocrine therapy. We hypothesized that ER drives development and progression of a subset of ovarian tumors and that outputs of ER function would identify patients who respond to endocrine therapy. We assessed endocrine response and mechanisms of ER signaling in models and clinical samples of high- grade serous ovarian cancer (HGSOC). These studies suggested that expression of ER target genes (ERTGs) reflect active ER in HGSOC and correspond with endocrine responsiveness. In light of this, we profiled ERTG expression to evaluate changes in ER signaling during the progression from benign endometriosis to endometriosis-associated cancer (EAOC). This analysis suggested that canonical ER signaling becomes largely inactivated during this transformation and that de-repressed genes (e.g. FGF18, ESR2) may contribute to the evolution of EAOC. Finally, we compared ER and ERTG expression between serous and mucinous low malignant potential (LMP) tumors. Serous LMP tumors have high expression of ER and several ERTGs (e.g. GREB1). Taken together, our findings describe biomarkers that could identify iv ovarian cancer patients across multiple disease subtypes who would benefit clinically from endocrine therapy. v TABLE OF CONTENTS PREFACE ................................................................................................................................. XIV 1.0 INTRODUCTION ........................................................................................................ 1 1.1 OVARIAN CANCER .......................................................................................... 1 1.1.1 Heterogeneity of epithelial ovarian cancer ................................................. 2 1.1.2 Ovarian cancer treatment paradigms ......................................................... 3 1.1.3 Targeted therapeutics in ovarian cancer .................................................... 4 1.1.4 Opportunities for personalized medicine in ovarian cancer ..................... 6 1.2 ESTROGEN IN OVARIAN CANCER PATHOBIOLOGY ........................... 7 1.2.1 Targeting estrogen receptor in cancer ........................................................ 8 1.2.2 Estrogen exposure and ovarian cancer risk ............................................... 9 1.2.3 Clinical trials of endocrine therapy in ovarian cancer ............................ 11 1.2.4 Identifying endocrine-responsive ovarian cancer .................................... 13 1.3 ESTROGEN REPEPTOR SIGNALING IN OVARIAN CANCER ............. 14 1.3.1 Overview of estrogen receptor signaling................................................... 14 1.3.2 Interplay between ER and PR in ovarian cancer .................................... 16 1.3.3 Preclinical studies of ER signaling in ovarian cancer.............................. 17 1.3.4 Novel models of ovarian cancer ................................................................. 19 vi 1.4 IMPLICATIONS FOR PERSONALIZED THERAPY FOR OVARIAN CANCER ............................................................................................................................. 21 2.0 BIOMARKERS OF ER FUNCTION REFLECT ENDOCRINE RESPONSE IN HIGH-GRADE SEROUS OVARIAN CANCER ..................................................................... 22 2.1 INTRODUCTION ............................................................................................. 22 2.2 MATERIALS AND METHODS ...................................................................... 23 2.2.1 Cell culture .................................................................................................. 23 2.2.2 Hormone deprivation.................................................................................. 24 2.2.3 In vitro proliferation and viability assays ................................................. 24 2.2.4 Cell line gene expression analyses ............................................................. 25 2.2.5 Xenograft studies ........................................................................................ 26 2.2.6 Immunoblots ................................................................................................ 26 2.2.7 Ex vivo cultures for rapid assessment of endocrine response ................. 27 2.2.8 Immunohistochemistry ............................................................................... 28 2.2.9 Development of the E2sig and EndoRx panel .......................................... 29 2.2.10 Analysis of clinical specimens .................................................................... 30 2.2.11 Statistical methods ...................................................................................... 31 2.3 RESULTS ........................................................................................................... 31 2.3.1 Endocrine response in HGSOC cell lines.................................................. 31 2.3.2 Endocrine response in HGSOC patient-derived xenografts ................... 36 2.3.3 Identifying genes associated with clinical endocrine response ............... 41 2.4 DISCUSSION ..................................................................................................... 45 3.0 UNDERSTANDING ER SIGNALING IN OVARIAN CANCER ........................ 48 vii 3.1 INTRODUCTION ............................................................................................. 48 3.2 MATERIALS AND METHODS ...................................................................... 49 3.2.1 Cell culture .................................................................................................. 49 3.2.2 Transient knockdown ................................................................................. 50 3.2.3 Gene expression analyses in HGSOC cell lines ........................................ 50 3.2.4 Immunoblots ................................................................................................ 50 3.3 RESULTS ........................................................................................................... 51 3.3.1 Evaluating DEPTOR as a potential mediator of endocrine response .... 51 3.3.2 Using changes in ER signaling between 2-D and ULA to identify ERTGs critical to growth ........................................................................................................ 52 3.3.3 Identifying pathways that crosstalk with ER ........................................... 56 3.3.4 Evaluating crosstalk between ER and IL-6/STAT signaling .................. 57 3.4 DISCUSSION ..................................................................................................... 59 4.0 EVOLUTION OF ESTROGEN SIGNALING IN THE PROGRESSION FROM ENDOMETRIOSIS TO ENDOMETRIOSIS-ASSOCIATED OVARIAN CANCER ......... 63 4.1 INTRODUCTION ............................................................................................. 63 4.2 MATERIALS AND METHODS ...................................................................... 64 4.2.1 Clinical specimens ....................................................................................... 64 4.2.2 RNA extraction and NanoString analysis ................................................. 65 4.2.3 Immunohistochemistry ............................................................................... 66 4.2.4 Statistical analysis ....................................................................................... 66 4.2.5 Gene set enrichment analysis (GSEA) ...................................................... 67 4.3 RESULTS ........................................................................................................... 67 viii 4.3.1 Identification of differentially expressed genes between normal, endometriosis, and cancer tissues ............................................................................. 67 4.3.2 Changes in hormone receptor expression and canonical ER signaling in EAOC…
Load more

Recommended publications
  • Analysis of Estrogen Receptor Isoforms and Variants in Breast Cancer Cell Lines
    EXPERIMENTAL AND THERAPEUTIC MeDICINE 2: 537-544, 2011 Analysis of estrogen receptor isoforms and variants in breast cancer cell lines MAIE AL-BADER1, CHRISTOPHER FORD2, BUSHRA AL-AYADHY3 and ISSAM FRANCIS3 Departments of 1Physiology, 2Surgery, and 3Pathology, Faculty of Medicine, Kuwait University, Safat 13110, Kuwait Received November 22, 2010; Accepted February 14, 2011 DOI: 10.3892/etm.2011.226 Abstract. In the present study, the expression of estrogen domain C, the DNA binding domain; domains D/E, bearing receptor (ER)α and ERβ isoforms in ER-positive (MCF7, both the activation function-2 (AF-2) and the ligand binding T-47D and ZR-75-1) and ER-negative (MDA-MB-231, SK-BR-3, domains; and finally, domain F, the C-terminal domain (6,7). MDA-MB-453 and HCC1954) breast cancer cell lines was The actions of estrogens are mediated by binding to ERs investigated. ERα mRNA was expressed in ER-positive and (ERα and/or ERβ). These receptors, which are co-expressed some ER-negative cell lines. ERα ∆3, ∆5 and ∆7 spliced in a number of tissues, form functional homodimers or variants were present in MCF7 and T-47D cells; ERα ∆5 heterodimers. When bound to estrogens as homodimers, the and ∆7 spliced variants were detected in ZR-75-1 cells. transcription of target genes is activated (8,9), while as heterodi- MDA-MB-231 and HCC1954 cells expressed ERα ∆5 and ∆7 mers, ERβ exhibits an inhibitory action on ERα-mediated gene spliced variants. The ERβ1 variant was expressed in all of the expression and, in many instances, opposes the actions of ERα cell lines and the ERβ2 variant in all of the ER-positive and (7,9).
    [Show full text]
  • The Rise and Fall of the Bovine Corpus Luteum
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Spring 5-6-2017 The Rise and Fall of the Bovine Corpus Luteum Heather Talbott University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Biochemistry Commons, Molecular Biology Commons, and the Obstetrics and Gynecology Commons Recommended Citation Talbott, Heather, "The Rise and Fall of the Bovine Corpus Luteum" (2017). Theses & Dissertations. 207. https://digitalcommons.unmc.edu/etd/207 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE RISE AND FALL OF THE BOVINE CORPUS LUTEUM by Heather Talbott A DISSERTATION Presented to the Faculty of the University of Nebraska Graduate College in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Biochemistry and Molecular Biology Graduate Program Under the Supervision of Professor John S. Davis University of Nebraska Medical Center Omaha, Nebraska May, 2017 Supervisory Committee: Carol A. Casey, Ph.D. Andrea S. Cupp, Ph.D. Parmender P. Mehta, Ph.D. Justin L. Mott, Ph.D. i ACKNOWLEDGEMENTS This dissertation was supported by the Agriculture and Food Research Initiative from the USDA National Institute of Food and Agriculture (NIFA) Pre-doctoral award; University of Nebraska Medical Center Graduate Student Assistantship; University of Nebraska Medical Center Exceptional Incoming Graduate Student Award; the VA Nebraska-Western Iowa Health Care System Department of Veterans Affairs; and The Olson Center for Women’s Health, Department of Obstetrics and Gynecology, Nebraska Medical Center.
    [Show full text]
  • Expression of Estrogen Receptor-Beta Isoforms in Barrett's
    ANTICANCER RESEARCH 24: 2919-2924 (2004) Expression of Estrogen Receptor-Beta Isoforms in Barrett’s Metaplasia, Dysplasia and Esophageal Adenocarcinoma LIANG LIU, MINNI CHIRALA and MAMOUN YOUNES Departments of Pathology, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, U.S.A. Abstract. We have previously shown that the majority of and beta (ER-B). ER-A is mainly expressed in female sex esophageal adenocarcinomas (EA), and its precursor Barrett’s organs, such as breast and uterus (2), whereas ER-B is metaplasia (BM), express estrogen receptor beta (ER-B). Several expressed in both sex organs and other tissues, such as isoforms of ER-B have been described and are presumed to have prostate, lung, thyroid, adrenal cortex and testis (3). Several different functions, but their distribution in BM and EA is not ER-B isoforms have been identified and characterized in known. The aim of this work was to determine which ER-B many non-gynecologic tumors including carcinomas of the isoforms are expressed in EA and BM. Sections of formalin-fixed lung (4), prostate (5), colon (6, 7) and stomach (8). and paraffin-embedded esophageal tissue from 33 esophageactomy Tamoxifen, a specific ER-B antagonist, has been successfully specimens, of which 27 had invasive EA, were stained for the ER- used in the treatment of patients with breast carcinoma B isoforms ER-B1, ER-B2, ER-B3 and ER-B5 utilizing the (9,10) and it has been shown that ER-B status is a significant immunoperoxidase method. ER-B1 was detected in 23 out of 27 predictor of survival in women with breast carcinoma treated (85%) EA compared to 3 out of 14 (21%) Barrett’s metaplasia with mastectomy and adjuvant tamoxifen (11).
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • SOX11 Interactome Analysis: Implication in Transcriptional Control and Neurogenesis
    SOX11 interactome analysis: Implication in transcriptional control and neurogenesis Dissertation der Mathematisch-Naturwissenschaftlichen Fakultät der Eberhard Karls Universität Tübingen zur Erlangung des Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) vorgelegt von Birgit Heim, geb.Kick aus Augsburg Tübingen 2014 Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Eberhard Karls Universität Tübingen. Tag der mündlichen Qualifikation: 12.02.2015 Dekan: Prof. Dr. Wolfgang Rosenstiel 1. Berichterstatter: Prof. Dr. Olaf Rieß 2. Berichterstatter: Prof. Dr. Marius Ueffing Für meine Familie TABLE OF CONTENTS Table of contents Summary ................................................................................................................ 5 Zusammenfassung ............................................................................................... 7 1. Introduction ...................................................................................... 9 1.1. Adult neurogenesis .................................................................................... 9 1.1.1. Adult neural stem cells and neuronal precursor cells ............................ 9 1.1.2. Neurogenic niches .............................................................................. 11 1.1.3. Regulation of adult neurogenesis ........................................................ 12 1.1.3.1. Extrinsic mechanisms .................................................................. 12 1.1.3.2. Intrinsic mechanisms ..................................................................
    [Show full text]
  • Differential Patterns of Allelic Loss in Estrogen Receptor-Positive Infiltrating Lobular and Ductal Breast Cancer
    GENES, CHROMOSOMES & CANCER 47:1049–1066 (2008) Differential Patterns of Allelic Loss in Estrogen Receptor-Positive Infiltrating Lobular and Ductal Breast Cancer L. W. M. Loo,1 C. Ton,1,2 Y.-W. Wang,2 D. I. Grove,2 H. Bouzek,1 N. Vartanian,1 M.-G. Lin,1 X. Yuan,1 T. L. Lawton,3 J. R. Daling,2 K. E. Malone,2 C. I. Li,2 L. Hsu,2 and P.L. Porter1,2,3* 1Division of Human Biology,Fred Hutchinson Cancer Research Center,Seattle,WA 2Division of Public Health Sciences,Fred Hutchinson Cancer Research Center,Seattle,WA 3Departmentof Pathology,Universityof Washington,Seattle,WA The two main histological types of infiltrating breast cancer, lobular (ILC) and the more common ductal (IDC) carcinoma are morphologically and clinically distinct. To assess the molecular alterations associated with these breast cancer subtypes, we conducted a whole-genome study of 166 archival estrogen receptor (ER)-positive tumors (89 IDC and 77 ILC) using the Affy- metrix GeneChip® Mapping 10K Array to identify sites of loss of heterozygosity (LOH) that either distinguished, or were shared by, the two phenotypes. We found single nucleotide polymorphisms (SNPs) of high-frequency LOH (>50%) common to both ILC and IDC tumors predominately in 11q, 16q, and 17p. Overall, IDC had a slightly higher frequency of LOH events across the genome than ILC (fractional allelic loss 5 0.186 and 0.156). By comparing the average frequency of LOH by chro- mosomal arm, we found IDC tumors with significantly (P < 0.05) higher frequency of LOH on 3p, 5q, 8p, 9p, 20p, and 20q than ILC tumors.
    [Show full text]
  • The Role of Transcription Factor in the Regulation of Autoimmune Diseases
    Chiba Medical J. 97E：17－24， 2021 doi:10.20776/S03035476-97E-2-P17 〔 Chiba Medical Society Award Review 〕 The role of transcription factor in the regulation of autoimmune diseases Akira Suto1,2) 1) Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba 260-8670. 2) Institute for Global Prominent Research, Chiba University, Chiba 260-8670. （Received November 14, 2020, Accepted December 9, 2020, Published April 10, 2021.） Abstract IL-21 is produced by Th17 cells and follicular helper T cells. It is an autocrine growth factor and plays critical roles in autoimmune diseases. In autoimmune mouse models, excessive production of IL-21 is associated with the development of lupus-like pathology in Sanroque mice, diabetes in NOD mice, autoimmune lung inflammation in Foxp3-mutant scurfy mice, arthritis in collagen-induced arthritis, and muscle inflammation in experimental autoimmune myositis. IL-21 production is induced by the transcription factor c-Maf following Stat3 activation on stimulation with IL-6. Additionally, Stat3 signaling induces the transcription factor Sox5 that along with c-Maf directly activates the promoter of RORγt, a master regulator of Th17 cells. Moreover, T cell-specific Sox5-deficient mice exhibit decreased Th17 cell differentiation and resistance to experimental autoimmune encephalomyelitis and delayed- type hypersensitivity. Another Sox family gene, Sox12, is expressed in regulatory T cells（ Treg） in dextran sulfate sodium-induced colitic mice. T cell receptor-NFAT signaling induces Sox12 expression that further promotes Foxp3 expression in CD4＋ T cells. In vivo, Sox12 is involved in the development of peripherally induced Treg cells under inflammatory conditions in an adoptive transfer colitis model.
    [Show full text]
  • Supplemental Table S1 (A): Microarray Datasets Characteristics
    Supplemental table S1 (A): Microarray datasets characteristics Title Summary Samples Literature ref. GEO ref. Acquisition of granule Gene expression profiling of 27 (1) GSE 11859 neuron precursor identity cerebellar tumors generated and Hedgehog‐induced from various early and late medulloblastoma in mice. stage CNS progenitor cells Medulloblastomas derived Study of mouse 5 (2) GSE 7212 from Cxcr6 mutant mice medulloblastoma in response respond to treatment with to inhibitor of Smoothened a Smoothened inhibitor Expression profiles of Identification of distinct classes 10 (3) GSE 9299 mouse medulloblastoma of up‐regulated or down‐ 339 & 340 regulated genes during Hh dependent tumorigenesis Genetic alterations in Identification of differently 10 (4) GSE 6463 mouse medulloblastomas expressed genes among CGNPs 339 & and generation of tumors and CGNPs transfected with 340 from cerebellar granule retroviruses that express nmyc neuron precursors or cyclin‐d1 Patched heterozygous Analysis of granule cell 14 (5) GSE 2426 model of medulloblastoma precursors, pre‐neoplastic cells, GDS1110 and tumor cells 1. Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh‐induced medulloblastoma. Cancer Cell 2008;14:123‐134. 2. Sasai K, Romer JT, Kimura H, Eberhart DE, Rice DS, Curran T. Medulloblastomas derived from Cxcr6 mutant mice respond to treatment with a smoothened inhibitor. Cancer Res 2007;67:3871‐3877. 3. Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, Rowitch D, et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res 2006;66:10171‐10178.
    [Show full text]
  • Common Single-Nucleotide Polymorphisms in the Estrogen Receptor B Promoter Are Associated with Colorectal Cancer Survival in Postmenopausal Women
    Published OnlineFirst November 13, 2012; DOI: 10.1158/0008-5472.CAN-12-2484 Cancer Prevention and Epidemiology Research Common Single-Nucleotide Polymorphisms in the Estrogen Receptor b Promoter Are Associated with Colorectal Cancer Survival in Postmenopausal Women Michael N. Passarelli1,2, Amanda I. Phipps1, John D. Potter1,2,3, Karen W. Makar1, Anna E. Coghill1,2, Karen J. Wernli3,4, Emily White1,2, Andrew T. Chan5,6, Carolyn M. Hutter1,2, Ulrike Peters1,2, and Polly A. Newcomb1,2 Abstract Loss of estrogen receptor b (ERb) expression in the gut is associated with colorectal cancer (CRC) initiation and progression. Germline single-nucleotide polymorphisms (SNP) in genes for the sex-steroid hormone receptors are not strongly associated with CRC risk; however, these SNPs have not previously been evaluated in relation to survival after diagnosis. We enrolled 729 women, ages 50 to 74, diagnosed with invasive CRC between 1997 and 2002 in 13 counties covered by the Seattle-Puget Sound Surveillance Epidemiology and End Results cancer registry. Participants provided germline DNA. We selected 99 tag-SNPs for the androgen receptor (AR), ERa (ESR1), ERb (ESR2), and progesterone receptor (PGR) genes. Mortality outcomes were ascertained from the National Death Index. During a median of 6.6 years of follow-up, 244 deaths occurred (161 from CRC). We identified 20 SNPs (12 of ESR2 and 8 of PGR) for replication in 1,729 women diagnosed with incident invasive CRC (555 deaths; 405 from CRC) from three prospective cohort studies that participate in the Genetics and Epidemiology of Colorectal Cancer Consortium. Three correlated SNPs in the promoter of ESR2 (rs2987983, rs3020443, and rs2978381) were statistically significant predictors of CRC-specific and overall survival.
    [Show full text]
  • Novel and Highly Recurrent Chromosomal Alterations in Se´Zary Syndrome
    Research Article Novel and Highly Recurrent Chromosomal Alterations in Se´zary Syndrome Maarten H. Vermeer,1 Remco van Doorn,1 Remco Dijkman,1 Xin Mao,3 Sean Whittaker,3 Pieter C. van Voorst Vader,4 Marie-Jeanne P. Gerritsen,5 Marie-Louise Geerts,6 Sylke Gellrich,7 Ola So¨derberg,8 Karl-Johan Leuchowius,8 Ulf Landegren,8 Jacoba J. Out-Luiting,1 Jeroen Knijnenburg,2 Marije IJszenga,2 Karoly Szuhai,2 Rein Willemze,1 and Cornelis P. Tensen1 Departments of 1Dermatology and 2Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands; 3Department of Dermatology, St Thomas’ Hospital, King’s College, London, United Kingdom; 4Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands; 5Department of Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; 6Department of Dermatology, Gent University Hospital, Gent, Belgium; 7Department of Dermatology, Charite, Berlin, Germany; and 8Department of Genetics and Pathology, Rudbeck Laboratory, University of Uppsala, Uppsala, Sweden Abstract Introduction This study was designed to identify highly recurrent genetic Se´zary syndrome (Sz) is an aggressive type of cutaneous T-cell alterations typical of Se´zary syndrome (Sz), an aggressive lymphoma/leukemia of skin-homing, CD4+ memory T cells and is cutaneous T-cell lymphoma/leukemia, possibly revealing characterized by erythroderma, generalized lymphadenopathy, and pathogenetic mechanisms and novel therapeutic targets. the presence of neoplastic T cells (Se´zary cells) in the skin, lymph High-resolution array-based comparative genomic hybridiza- nodes, and peripheral blood (1). Sz has a poor prognosis, with a tion was done on malignant T cells from 20 patients. disease-specific 5-year survival of f24% (1).
    [Show full text]
  • Loss of MGA Repression Mediated by an Atypical Polycomb Complex
    RESEARCH ARTICLE Loss of MGA repression mediated by an atypical polycomb complex promotes tumor progression and invasiveness Haritha Mathsyaraja1, Jonathen Catchpole1, Brian Freie1, Emily Eastwood2, Ekaterina Babaeva1, Michael Geuenich1, Pei Feng Cheng1, Jessica Ayers3, Ming Yu3, Nan Wu2, Sitapriya Moorthi2, Kumud R Poudel1, Amanda Koehne4, William Grady3,5, A McGarry Houghton2,3, Alice H Berger2, Yuzuru Shiio6, David MacPherson2*, Robert N Eisenman1* 1Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States; 2Human Biology and Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle, United States; 3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, United States; 4Comparative Pathology, Fred Hutchinson Cancer Research Center, Seattle, United States; 5Department of Medicine, University of Washington School of Medicine, Seattle, United States; 6Greehey Children’s Cancer Research Institute, The University of Texas Health Science Center, San Antonio, United States Abstract MGA, a transcription factor and member of the MYC network, is mutated or deleted in a broad spectrum of malignancies. As a critical test of a tumor suppressive role, we inactivated Mga in two mouse models of non-small cell lung cancer using a CRISPR-based approach. MGA loss significantly accelerated tumor growth in both models and led to de-repression of non-canonical Polycomb ncPRC1.6 targets, including genes involved in metastasis and meiosis. Moreover, MGA deletion in human lung adenocarcinoma lines augmented invasive capabilities. We further show that MGA-MAX, E2F6, and L3MBTL2 co-occupy thousands of promoters and that MGA stabilizes these ncPRC1.6 subunits. Lastly, we report that MGA loss also induces a pro-growth effect in *For correspondence: human colon organoids.
    [Show full text]
  • Irf1) Signaling Regulates Apoptosis and Autophagy to Determine Endocrine Responsiveness and Cell Fate in Human Breast Cancer
    INTERFERON REGULATORY FACTOR-1 (IRF1) SIGNALING REGULATES APOPTOSIS AND AUTOPHAGY TO DETERMINE ENDOCRINE RESPONSIVENESS AND CELL FATE IN HUMAN BREAST CANCER A Dissertation Submitted to the Faculty of the Graduate School of Arts and Sciences of Georgetown University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Physiology & Biophysics By Jessica L. Roberts, B.S. Washington, DC September 27, 2013 Copyright 2013 by Jessica L. Roberts All Rights Reserved ii INTERFERON REGULATORY FACTOR-1 (IRF1) SIGNALING REGULATES APOPTOSIS AND AUTOPHAGY TO DETERMINE ENDOCRINE RESPONSIVENESS AND CELL FATE IN HUMAN BREAST CANCER Jessica L. Roberts, B.S. Thesis Advisor: Robert Clarke, Ph.D. ABSTRACT Interferon regulatory factor-1 (IRF1) is a nuclear transcription factor and pivotal regulator of cell fate in cancer cells. While IRF1 is known to possess tumor suppressive activities, the role of IRF1 in mediating apoptosis and autophagy in breast cancer is largely unknown. Here, we show that IRF1 inhibits antiapoptotic B-cell lymphoma 2 (BCL2) protein expression, whose overexpression often contributes to antiestrogen resistance. We proposed that directly targeting the antiapoptotic BCL2 members with GX15-070 (GX; obatoclax), a BH3-mimetic currently in clinical development, would be an attractive strategy to overcome antiestrogen resistance in some breast cancers. Inhibition of BCL2 activity, through treatment with GX, was more effective in reducing the cell density of antiestrogen resistant breast cancer cells versus sensitive cells, and this increased sensitivity correlated with an accumulation of autophagic vacuoles. While GX treatment promoted autophagic vacuole and autolysosome formation, p62/SQSTM1, a marker for autophagic degradation, levels accumulated.
    [Show full text]